Melatonin modulates aromatase activity and expression in endothelial cells

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 2058-2064

  Alvarez García, Virginia ^a   González, Alicia ^a   Martínez Campa, Carlos ^a   Alonso González, Carolina ^a   Cos, Samuel ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Aromatase; HUVECs; Melatonin; Pineal gland

Indexed keywords

AROMATASE; ESTROGEN; MELATONIN; MESSENGER RNA; TESTOSTERONE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL;

AROMATASE; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; ESTROGENS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELATONIN; PROMOTER REGIONS, GENETIC; TESTOSTERONE;

EID: 84876228772     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2314     Document Type: Article

References (50)

1. Russo IH and Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61, 1998. (Pubitemid 128513219)
2. Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96, 2006. (Pubitemid 44750629)
3. Orlando L, Schiavone P, Fedele P, et al: Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev 36 (Suppl 3): S67-S71, 2010.
4. Landeghem AA, Poortman J, Nabuurs M and Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900-2906, 1985. (Pubitemid 15232767)
5. Bulun SE, Lin Z, Imir G, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57: 359-383, 2005. (Pubitemid 41196955)
6. Bulun SE, Price TM, Aitken J, Mahendroo MS and Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrin Metab 77: 1622-1628, 1993. (Pubitemid 24000924)
7. Yue W, Wang JP, Hamilton CJ, Demers LM and Santen RJ: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58: 927-932, 1998. (Pubitemid 28182460)
8. Santen RJ and Harvey HA: Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 6: 75-92, 1999. (Pubitemid 29197232)
9. Brodie AM and Njar VC: Aromatase inhibitors and their application in breast cancer treatment. Steroids 65: 171-179, 2000. (Pubitemid 30129250)
10. Hill SM and Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48: 6121-6126, 1988. (Pubitemid 18266811)
11. Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170, 2000. (Pubitemid 30228502)
12. Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem 2: 113-132, 2002.
13. Mediavilla MD, Sánchez-Barceló EJ, Tan DX, Manchester L and Reiter RJ: Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17: 4462-4481, 2010.
14. Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159, 2003. (Pubitemid 36758644)
15. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006. (Pubitemid 43766230)
16. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691-702, 2008.
17. González A, Cos S, Martínez-Campa C, Alonso-González C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92, 2008.
18. Zhou D, Wang J, Chen E, Murai J, Siiteri PK and Chen S: Aromatase gene is amplified in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 46: 147-153, 1993. (Pubitemid 23251672)
19. Ram PT, Kiefer T, Silverman M, Song Y, Brown GM and Hill SM: Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Mol Cell Endocrinol 141: 53-64, 1998. (Pubitemid 28393379)
20. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L and Hill SM: Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 179: 141-150, 2002. (Pubitemid 34215105)
21. Cos S, Martínez-Campa C, Mediavilla MD and Sánchez- Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142, 2005. (Pubitemid 40293239)
22. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez- Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278, 2006. (Pubitemid 41779064)
23. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM and Bulun SE: Tumor necrosis factor a and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ: mechanism of desmoplastic reaction. Cancer Res 61: 2250-2255, 2001. (Pubitemid 32692055)
24. Bulun SE, Chen D, Lu M, et al: Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 106: 81-96, 2007. (Pubitemid 47362640)
25. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 52: 282-290, 2012.
26. González A, Alvarez-García V, Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res 52: 12-20, 2012.
27. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H and Takagi Y: Localized expression of aromatase in human vascular tissues. Circ Res 84: 1285-1291, 1999. (Pubitemid 29270043)
28. Mukherjee TK, Dinh H, Chaudhuri G and Nathan L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 6: 4055-4060, 2002. (Pubitemid 34252228)
29. Sebastian S and Bulun SE: A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the human genome project. J Clin Endocrinol Metab 10: 4600-4602, 2001. (Pubitemid 33020491)
30. Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S and Chen D: Regulation of aromatase expression in breast cancer tissue. Ann NY Acad Sci 1155: 121-131, 2009.
31. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H and Bulun SE: Regulation of breast cancer-associated aromatase promoters. Cancer Lett 273: 15-27, 2009.
32. Sebastian S, Takayama K, Shozu M and Bulun SE: Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol Endocrinol 10: 2243-2254, 2002. (Pubitemid 35155537)
33. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Álvarez-García V, Sánchez- Barceló EJ and Cos S: Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 101: 1613-1619, 2009.
34. González A, Martínez-Campa C, Mediavilla MD, et al: Effects of MT1 melatonin receptor overexpression on the aromatase-supressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 4: 947-953, 2007.
35. Cui P, Luo Z, Zhang H, et al: Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 4: 358-362, 2006. (Pubitemid 44498222)
36. Cui P, Yu M, Luo Z, Dai M, Han J, Xiu R and Yang Z: Intracellular signaling pathways involved in cell growth inhibition of human vein endothelial cells by melatonin. J Pineal Res 44: 107-114, 2008. (Pubitemid 350231103)
37. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC and Simpson ER: Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 53: 412-417, 1981. (Pubitemid 13250304)
38. Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654: 123-143, 2004.
39. Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93: 221-236, 2005. (Pubitemid 40602495)
40. Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15: 637-647, 2000. (Pubitemid 30218860)
41. Molis TM, Spriggs LI and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
42. Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64: 249-256, 1992.
43. Garvin S, Nilsson UW and Dabrosin C: Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1 and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 9: 1005-1010, 2005. (Pubitemid 41548394)
44. González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br J Cancer 97: 755-760, 2007. (Pubitemid 47396286)
45. Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER and Clyne CD: Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat 132: 765-771, 2012.
46. Turner HE, Harris AL, Melmed S and Wass JA: Angiogenesis in endocrine tumors. Endocr Rev 24: 600-632, 2003. (Pubitemid 37330584)
47. García-Santos G, Antolín I, Herrera F, Martín V, Rodriguez-Blanco J, del Pilar Carrera M and Rodriguez C: Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 41: 130-135, 2006. (Pubitemid 44141747)
48. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63: 29-43, 2005. (Pubitemid 40365388)
49. Longatti P, Perin A, Rizzo V, Comai S, Giusti P and Costa CV: Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. J Pineal Res 42: 113-118, 2007. (Pubitemid 46233055)
50. Maestroni GJ and Conti A: Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab Invest 75: 557-561, 1996. (Pubitemid 26346805)